Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR
Marketer
Danavish Healthcare
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR
Danavish Glimepiride/Metformin/Voglibose (2mg/500mg/0.2mg) extended-release tablets are a triple-combination antidiabetic medication for adult patients with type 2 diabetes. This formulation helps manage blood glucose levels. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation can lead to elevated blood sugar, increasing the risk of complications including kidney disease, vision impairment, neuropathy, and limb loss. This medication forms part of a comprehensive diabetes management plan, incorporating diet, exercise, and weight management as directed by your doctor. Hypoglycemia (low blood sugar) is a prevalent side effect. Familiarize yourself with its symptoms (sweating, dizziness, headache, tremor) and appropriate countermeasures (fast-acting glucose source). Alcohol consumption elevates hypoglycemia risk and should be limited. Other potential adverse effects include altered taste, nausea, diarrhea, abdominal discomfort, cephalgia, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain is also possible. Contraindications include type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Individuals with a history of cardiac disease should inform their physician before commencing treatment. Consult your doctor before use during pregnancy or breastfeeding. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, are recommended.
Uses of Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR
Managing type 2 diabetes
Major Benefits of Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Extended-Release tablets should be administered on an empty stomach.
Common Side effects of Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg SR tablets should be administered on an empty stomach.
How Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR works:
Each Danavish tablet (SR) combines glimepiride (2mg), metformin (500mg), and voglibose (0.2mg) to manage diabetes mellitus.
SAFETY ADVICE
AlcoholUNSAFE
Combining Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg SR tablets with alcohol is inadvisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
The combination medication Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg SR tablets may pose risks during pregnancy. While human research is scant, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against potential hazards before prescribing. Patient consultation with their doctor is advised.
Breast feedingCONSULT YOUR DOCTOR
The combined medication Danavish, containing glimepiride, metformin, and voglibose (2mg/500mg/0.2mg sustained-release tablets), is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Impaired driving is possible with severely low or high blood glucose levels. Refrain from driving if such symptoms arise.
KidneyUNSAFE
Individuals with kidney impairment should likely avoid Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg SR tablets due to potential safety concerns. Medical advice is essential. Moreover, this medication is unsuitable for those with severe kidney disease.
LiverCAUTION
Patients with liver disease should use Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is advised. In individuals with mild to moderate liver impairment, initiation with a low dose of Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR is typical; however, its use is contraindicated in those with severe liver disease.
What if you forget to take Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR :
Should you forget a dose of your Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg SR tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Danavish Glimepiride+Metformin+Voglibose 2mg/500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Diabetes Management |
3,018 People bought this recently